^
Association details:
| Biomarker: | miR-216a-3p overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
Published date:
09/21/2020
Excerpt:
...we analyzed the relationship between miR-216a-3p levels and tumor regression after sorafenib treatment by estimating miR-216a-3p expression levels in pretreatment biopsy tumor specimens from 51 HCC patients who received sorafenib with or without surgery. The miR-216a-3p levels were significantly higher in HCC patients that showed a positive response to sorafenib treatment compared to those with minimal or no response to sorafenib treatment...
DOI:
10.18632/aging.103670